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Abstract Heparin cofactor II (HCII) is a 66 kDa plasma 
glycoprotein that belongs to the serpin superfamily of protease 
inhibitors. Its natural target is thrombin. HCII inhibits thrombin 
in both a progressive reaction, and in an accelerated reaction 
catalyzed by a glycosaminoglycan, dermatan sulphate (DS). Both 
modes of inhibition result in the formation of a stable, denatura- 
tion-resistant complex. Using a cDNA clone encoding rabbit 
HCII recently isolated and characterized in our laboratory, we 
have employed deletion mutagenesis to identify amino-terminal 
regions of the molecule which are essential to the progressive 
reaction. PCR was employed to produce four deletion constructs: 
zi58, A81, A106, and A169, all in an in vitro transcription vector 
plasmid background. Transcription of the full-length construct, 
and of the four deletion constructs, followed by in vitro translation 
in rabbit reticulocyte lysate, was used to produce the correspond- 
ing HCII-related polypeptides. The A106 and zi169 mutants 
failed to react with thrombin, even in the presence of DS. In 
contrast, the A58 and A82 mutants retained the ability to form 
complexes with thrombin, although the rate of complex formation 
was decreased for the latter mutant compared to the full-length 
recombinant HCII; no acceleration of complex formation in the 
presence of 20 ~g/ml DS was noted for either truncated recombi- 
nant HCII. Alignment of the rabbit HCII primary structure with 
secondary structural elements found in oqantitrypsin and other 
serpins showed that the non-functional A106 mutant lacks helix 
A, while the functional A82 mutant contains this element. Our 
results suggest hat helix A is an essential part of a functional 
serpin, and define the limits of the amino-terminal region of HCII 
which is not essential for thrombin inhibition. 
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1. Introduction 
The serpins are members of a superfamily of serine protease 
inhibitors, many of which play important roles in the regulation 
of coagulation, fibrinolysis, or inflammation [1,2]. These re- 
lated proteins hare approximately 30% amino acid identity, as 
well as a common mechanism of action. This involves attack 
by target proteases at the reactive site of the inhibitor, followed 
by formation of a stable, 1:1 complex in which both protease 
and inhibitor are inactive [14]. 
Serpin regulation of thrombin is important in hemostasis, as 
shown by the thrombophilic tendencies of individuals geneti- 
cally deficient in a serpin called antithrombin, or antithrombin 
III (AT, or AT-III) [5-7]. Although AT is the principal inhibi- 
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tor of thrombin found in plasma, another serpin, called heparin 
cofactor II (HCII) also contributes to the control of thrombin 
[8]. While the AT-thrombin reaction is stimulated maximally by 
heparin [9], or heparan sulphate moieties, that of HC-II with 
thrombin is accelerated most effectively by dermatan sulphate 
[10]. The latter characteristic suggests that HC-II may play a 
role in the extravascular control of thrombin, because of the 
natural location of dermatan sulphate moieties [11]. 
While much has been learned concerning the structure and 
function of both active and inactive serpins, the molecular 
details of how serpins function remain to be worked out. Anal- 
ysis of point mutations, both natural and engineered, has con- 
tributed to our understanding of the importance ofthe reactive 
centre region, and to other egions of serpin molecules involved 
in cofactor interactions (for reviews, see [12,13]). We have cho- 
sen to use deletion mutagenesis to map the minimum essential 
form of HCII that is sufficient for complex formation with 
thrombin. HCII was selected over AT because of its lack of 
disulphide bonding, and because we have recently demon- 
strated that its expression i  rabbit reticulocyte lysate systems 
yields a more functional product than that of AT [14]. Our 
results uggest that the helix A structural element isan essential 
part of a functional serpin. 
2. Materials and methods 
2.1. Materials 
Human ~-thrombin (>3300 NIH units/mg; >93% active) was kindly 
provided by Dr. J. Fenton (New York State Division of Biologicals, 
Albany, NY). Plasmid vector pSV3 was the generous gift of Dr. David 
Andrews (McMaster University, Hamilton, Ontario). All restriction, 
DNA modifying enzymes, RNase inhibitors, ribo- and deoxyribonucle- 
otides, and mRNA CAP analog 7-methlyguanosylguanosine tri- 
phosphate [mTG(5')ppp(5')G] were purchased from Promega Biotec 
(Madison, WI). The latter was also the source of rabbit reticulocyte 
lysate and plasmid pGEM5zf+. The thrombin inhibitor D-phenyla- 
lanyl-L-propyl-arginine chloromethyl ketone (PPACK) (>99% active) 
was purchased from Calbiochem (Mississauga, ON). T7 sequencing 
kits were from Pharmacia LKB Biotechnology (Baie d'Urf~, QC). 
Translation grade [35S]methionine (>1000 Ci/mmol, 10 ¢tCi//A) was 
from NEN-DuPont (Mississauga, ON). Protein molecular weight stan- 
dards were from BioRad Laboratories (Oakville, ON). Oligonucleo- 
tides were synthesized at the Institute for Molecular Biology and Bio- 
technology, McMaster University, Hamilton, Ontario. All other chem- 
icals and reagents not specifically listed here were of the highest quality 
available. 
2.2. PCR and plasmid manipulations 
In order to generate plasmid transcription templates encoding 
amino-terminal truncations ofrabbit HCII, PCR was employed, using 
the previously described plasmid pMHC3 as template [14], and the M 13 
universal primer (Pharmacia) nd a mutagenic HCII-specific oligonu- 
cleotide as primers. Constructs, and the truncated HCII protein they 
encode, are named for the number of amino acids deleted. The specific 
primers were as follows: for the A169 construct, primer 3838 was used 
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(5'-TCATGACGCATCGCCTCTTCAGGA-3'); for the AI06 con- 
struct, primer 4114 was used (5'-CCATGGCCAACGCTTTTGATA- 
ACATC-3'); and for the A58 construct, primer 3839 was used (5'- 
TCATGATCATCGACGCTGTTTCCC-3'). PCR conditions were ex- 
actly as previously described [14]. After PCR, each product was made 
blunt-ended with Klenow fragment, gel-purified from agarose, and 
introduced into the EcoRV site of pGEM3zf+ by standard methods of 
ligation and transformation [15]. The orientation of the insert was 
determined by restriction endonuclease digestion, and purified DNA 
was prepared for in vitro transcription by linearization with either 
EeoRI or SacII. For theA81 construct, a slightly different approach was 
used, one that exploited the proximity of a unique BamHI site in the 
rabbit HCII cDNA. Two oligonucleotides, primer 4609 (5'-CATGA- 
AAGAGCAG-3') and primer 4610 (5'-GATCCTGCTCTT-3') were 
annealed as described [16], then combined with a 1790 bp BamHI 
EcoRI restriction fragment of pMHC3 and NcoI EcoRI digested tran- 
scription plasmid pSV3 [17] in a three-part ligation. 
2.3. In vitro transcription and translation 
Transcription plasmids were transcribed invitro from phage promot- 
ers; the A169, 106, and 58 constructs using T 7 polymerase, and the A81 
construct using SP 6 polymerase, as described previously [14]. Transla- 
tion was performed as described [14,18], in a messenger-dependent 
reticulocyte lysate supplemented with [35S]methionine. Following trans- 
lation, products were dialyzed overnight versus Tris-buffered saline at 
4 °. For thrombin-complexing assays, ~-thrombin was employed at a 
final concentration f0.85 pM; this represents atleast a 100-fold molar 
excess over the concentration f recombinant serpin in the reaction [18]. 
2.4. Miscellaneous 
SDS-PAGE analysis, followed by fluorography and autoradiogra- 
phy, was as described [14,18]. Reactions of cell-free derived HCII and 
its derivatives with thrombin were also monitored as described in these 
references, with the exception that the different truncated product prep- 
arations were diluted with 30 mg/ml bovine hemoglobin i  Tris-buff- 
ered saline to provide quivalent concentrations of radiolabeled HCII 
derivatives, while maintaining the same total protein concentrations 
between reactions. Quantitation of autoradiographic images was done 
using a Molecular Dynamics PhosporImager equipped with 
ImageQuant software. 
3. Results 
3.1. Cell-free synthesis of  truncated HCI I  proteins 
Recently, we described the primary sequence of rabbit HCII ,  
and showed that cell-free derived rabbit HCI I  was fully reactive 
with human ~-thrombin, in a reaction that could be accelerated 
by the addition of dermatan sulphate (DS). In the present 
study, we have applied the same experimental approach, 
namely synthesis in an in vitro, rabbit reticulocyte lysate trans- 
lation system, to produce truncated forms of recombinant rab- 
bit HCII.  
Fig. 1 summarizes the forms of rabbit HCI I  which were 
produced and synthesized in this study. As previously demon- 
strated, the principal product of cell-free translation of the 
template encoding the entire mature HCII  is a 50.8 kDa 
polypeptide that most likely arises due to translational initia- 
tion at Met-15 (Upper panel, lane 1). No difference in the rate 
of either progressive or DS-accelerated thrombin inhibition is 
seen when the 52.4 kDa full-length product is compared to the 
more prominent Met-15 product [14]. The products of the four 
truncated transcription templates that were generated are also 
shown in Fig. 1. The major products are of expected size: A169, 
33.4 kDa; A106, 40.4 kDa; A81, 43.4 kDa; and A58, 45.7 kDa. 
Other minor products of more rapid mobility than the major 
product are also seen, varying in abundance between transcrip- 
tion templates. For instance, a 39 kDa polypeptide product is 
found along with all synthesis reactions except for the A169 
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Fig. 1. Gel analysis of cell-free derived recombinant rabbit HCI] and 
derivatives. Upper panel: in vitro translation products were electro- 
phoresed on a 10% SDS-polyacrylamide gel, and radiolabeled proteins 
detected following fluorography and autoradiography. Lane 1, full 
length recombinant rabbit HCII (showing the prominent AI 5 internal 
product); lane 2, A106; lane 3, A169; lane 4, A81 (showing the A123 
internal product); lane 5, A58. The positions of the major protein species 
produced are indicated at right. The lower panel shows a schematic 
diagram of rabbit HCII derivatives and predicted structural elements. 
Uppermost line diagram shows a linear representation f full length 
recombinant rabbit HCII, engineered tocontain an N-terminal Met for 
cell free-synthesis (M). Diagram is to scale for residues 1~00 (ex- 
ploded) and not to scale for residues 201461. Helix A, hA; helices B, 
C, and D, hB,C,D. The two large negative signs highlight he position 
of the N-terminal hirudin-like acidic repeats. Solid bars, below, deline- 
ate the extent of the different N-terminally truncated molecules gener- 
ated in this study, named at right. Deliberately engineered constructs 
contain an added N-terminal Met residue; products generated by inter- 
nal initiation lack this extra amino acid. 
reaction, and is particularly prominent in the A58 reaction. This 
profile suggests that it is the product of  internal initiation at a 
Met residue amino-terminal to residue 169; given that Met 
residues are found only at positions 15 and 123, this product 
most likely arises from internal initiation at Met-123. 
3.2. Reaction of  HCI I  derivatives with thrombin 
Fig. 2 shows the results of an experiment in which the ability 
of the full-length HCII  to form complexes with thrombin was 
compared with that of the two most truncated deletion mu- 
tants, A169 and A106. After 10 minutes of reaction, thrombin- 
dependent species of 89 and 87 kDa were prominently visible, 
and the input full-length and the internal A15 species concor- 
dantly diminished (lanes 2 and 3), either in the presence (lane 
2 or absence (lane 3) of DS. Densitometry revealed that 64% 
of the input HCI I  had been consumed after 10 minutes of  
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Fig. 2. Reaction of thrombin with cell-free derived rabbit HCII, A106, 
and A 169. In vitro translation products were reacted with thrombin for 
0 (lanes 1, 4, and 7), or 10 minutes, in the absence (lanes 2, 5, and 8) 
or presence (lanes 3, 6 and 9) ofdermatan sulfate. Lanes 1 3, full-length 
HCII; lanes 4--6, A106; lanes 7-9, A169. 
reaction in the absence of DS, while in 1 minute 82% of input 
HCII was consumed in its presence. In contrast, neither any 
higher molecular weight products of lesser mobility than the 
input HCII species, nor any dimunition of input band intensi- 
ties is observable in the case of either A169 or A106 (Fig. 2, lanes 
5 and 6, and 8 and 9), even upon prolonged overexposure of
the autoradiogram (not shown). 
In contrast to the inactive status of the most truncated ele- 
tion mutants, two deletion mutants with lesser truncations re- 
tained some measure of thrombin reactivity. As shown in Fig. 
3, the A58 mutant formed complexes with thrombin with similar 
kinetics to the full-length or A15 forms in the absence of DS; 
quantitation showed that 59.4% of input A58 was consumed 
within 10 minutes of thrombin addition, as compared to 64.8% 
of input full-length recombinant HCII. In the presence of 20 
/Jg/ml DS, a concentration which we have determined is suffi- 
cient to give the maximal response in this system (not shown), 
no acceleration ofcomplex formation was seen. In contrast, the 
full-length HCII was largely consumed in less than 1 minute 
when this level of DS was provided in the reaction. Similar 
results were observed when the A82 mutant was analyzed in the 
same way as the A58 mutant, in that complex formation was 
observable, and that this complexing was not accelerated by 
DS. However, the extent of complex formation was somewhat 
reduced, when compared to that observed with the full-length 
rHCII, in that only 35.1% of input A81 was consumed by 
thrombin in 10 minutes, as compared to 63.8% of the input 
full-length rHCII. The lack of reactivity of the A123 HCII 
species, which is a prominent side-product of the 358 reaction, 
is consistent with the inactivity of the A169 and A 106 products. 
4. Discussion 
Our objective in this study was to define the minimum do- 
main(s) of rabbit HCII required for complex formation with 
thrombin. Our approach, that of generating a series of amino- 
terminal deletions of the protein, was determined by several 
factors. Firstly, the greatest degree of divergence between 
human and animal HCII primary structures is seen in this 
region [14], a difference that suggested that this region could 
be altered without abrograting the function of the molecule. 
Secondly, we had previously demonstrated [14] that an inter- 
nally initiated cell-free synthesis product lacking the first 15 
amino acid residues of the protein was just as active as the 
full-length product. Thirdly, Tollefsen and colleagues had pre- 
viously shown, using recombinant forms of the highly homolo- 
gous human AT expressed in bacteria, that the amino-terminus 
of the protein was important for glycosaminoglycan-acceler- 
ated thrombin inhibition. The proximity of the reactive centre 
of the molecule (Leu425-Ser426) to the carboxyl terminus, and 
the abundance of naturally occuring mutants that abrogate 
serpin function found in this area [12], was also a consideration 
in choosing to perform deletion analysis on the amino-terminal 
end of the molecule. 
The initial mutant hat we generated was A 169. This deletion 
was essentially selected as a random deletion of the amino- 
terminal third of the molecule, and was planned to establish a
benchmark on the HCII polypeptide chain. Functional A169 
would indicate that more extensive deletions were required; 
non-functional A169 would suggest that less extensive deletions 
should next be attempted. As shown in Fig. 2, A169 failed to 
form complexes with thrombin. Inspection of HCII aligned 
with secondary structural elements found in ~lantitrypsin and 
other serpins (Fig. 1) revealed that helices A through D as well 
as intervening fl-stranded regions had been largely removed 
from the molecule. Accordingly, these regions were 'added 
back' in subsequent deletions. 
Two acidic sequence motifs are found in the first 58 amino 
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3.3. Alignment of deletion mutants with known and predicted 
structural elements" 
The schematic diagram shown in the lower panel of Fig. 1 
summarizes the amino-terminal truncations produced in this 
study, either deliberately through DNA manipulations, or ser- 
endipitously, via internal initiation. While A82 retained progres- 
sive thrombin inhibitory capacity, 3106 was devoid of activity. 
This suggests that an essential structural or functional element 
lies between these two residues on HCII. Comparison to serpin 
secondary structural elements mapped onto a linear display of 
the rabbit HCII (Fig. l) highlights the fact that helix A is found 
at this position. 
81 
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Fig. 3. Reaction of thrombin with cell-free derived rabbit HCII, A58, 
and A81. In vitro translation products were reacted with thrombin for 
0 (lanes 1 and 6), I (lanes 2 and 7), 2 (lanes 3 and 8), 5 (lanes 4 and 9), 
or 10 minutes (lanes 5 and 10) in the absence (lanes 1-5) or presence 
(lanes 6-10) of dermatan sulphate. Top panel, reaction of thrombin 
with full-length HCII; middle panel, reaction of thrombin with A58; 
bottom panel, reaction of thrombin with A81. 
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acids of rabbit HCII (corresponding to the first 74 amino acids 
of the human molecule), both containing a Glu-Asp-Asp-Asp- 
Tyr pentapeptide. It has been shown previously [19,20] that 
deletion of the first 74 amino acids of human HCII expressed 
in bacteria resulted in an HCII protein with greatly reduced 
DS-accelerated inhibitory activity. We made the corresponding 
deletion in rabbit HCII, and expressed the mutant/158 polypep- 
tide. As shown in Fig. 3, A58 retained the ability to react with 
thrombin in the progressive r action, but lost the ability to react 
in a fashion accelerated by DS. Our results are therefore n- 
tirely consistent with the more quantitative analysis performed 
on the recombinant human HCII. 
Provision of helices B through D and connecting domains in 
mutant A106 failed to restore antithrombin activity (Fig. 3). 
However, provision of the additional 24 amino acids predicted 
to comprise helix A, in mutant A81, restored the thrombin 
inhibitory capacity of the molecule. The properties of A81 
ressemble those of A58, in that no effect of DS was seen; how- 
ever, the extent and speed of complex formation of this pol- 
ypeptide was somewhat decreased compared to the full-length 
rHCII. 
Is the observed requirement for helix A structural or mecha- 
nistic? While neither HCII nor ~jantitrypsin have been crystal- 
lized in intact form, the latter serpin has been crystallized as a 
cleaved form [21], and the crystallization of plakalbumin [22], 
ovalbumin [23], the latent form of PAl-1 [24], and most recently 
a dimer of AT consisting of one active molecule linked to an 
inactive one [25], have yielded good structural models of intact 
serpins. Inspection of schematic representations of alAT and 
AT show that helix A traverses the molecule, underpinning the 
primarily fl-sheeted structures above it. Helix A appears to 
stabilize helices G and H [21,25]. This interpretation is sup- 
ported by a naturally occuring mutation of ctEAT, the I variant, 
that maps to helix A; in this variant Arg-39 (corresponding to
Arg-101 in rabbit HCII) is altered to Cys, eliminating the inter- 
helical contacts, and giving rise to a dysfunctional, partially 
destabilized antitrypsin [26]. Alterations to Arg-47 of the A 
helix of antithrombin are associated with decreased heparin 
affinity [27,28]; these point mutations would be expected to 
create only localized istortions of the extreme N-terminal por- 
tions of the helix, as opposed to the more critical alteration seen 
in SlAT I. Taken together with the results presented in this 
report, these structural data and interpretations support the 
contention that helix A is an essential part of a functional 
serpin, and suggest that its contribution is of importance chiefly 
in supporting the structural integrity of serpin molecules. 
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